Collins Helen Louise sold $293K of ELVN
Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $58.59 ($58.37–$59.35, $0.29M total) across 2 trades on 2026-08-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The sale is modest and likely reflects a pre‑planned 10b5‑1 execution rather than new information about company performance.
Market read
Provides a routine insider transaction update with limited trading relevance.
What to watch
Potential upcoming clinical data could be the real driver of future price moves.
Background
Form 4 filing discloses insider transactions required by SEC, providing transparency on insider holdings.
Ticker impact
Chief Medical Officer sold 5,000 shares for $292,931 via a 10b5-1 plan, reducing holdings to 25,000 shares.
Potential slight downward pressure, unlikely to move price materially.
Sale amount is under $300k and represents a small percentage of insider holdings; market may view as routine.
Market effects
Minimal impact on biotech sector; typical insider transaction.
None
None
Counterpoint
Insider may be reallocating capital; sale does not imply negative outlook.
Key entities
- CompanyEnliven Therapeutics, Inc.
Biotech firm developing therapies; ticker ELVN.
- InsiderHelen Louise Collins
Chief Medical Officer of Enliven Therapeutics.